Posted by Michael Wonder on 05 Apr 2021
FDA approvals strengthen Octapharma USA paediatric critical care product portfolio
30 March 2021 - Octaplas and fibryga receive new product labeling following FDA’s approval of BLA supplements to update therapy research.
The U.S. FDA has approved two Octapharma supplements to Biological License Applications, strengthening the company’s paediatric critical care product portfolio.
